How the Model Works
Partner with Your Practice
We work with uro-oncologists, urology and oncology groups that have patients who may benefit from radioligand therapy.
Choose the Right Partnership Model
Together, we find a partnership model that works for both sides from a referral or service agreement to a joint venture, tailored to your practice and patient volume.
ParticleX Builds and Operates the Center
We build out, equip, and operate the radioligand therapy center, including the specialized infrastructure, clinical team, and treatment capabilities.
Your Patients Stay with Your Practice
You remain the patient’s primary oncologist, ParticleX provides the radioligand therapy and coordinates treatment with your clinical team.
Our Vision
Radioligand therapy is becoming part of mainstream oncology and moving into earlier lines of treatment.
ParticleX is building a theranostics platform around this shift, starting with Lutetium-177 PSMA therapy for prostate cancer, and creating the clinical infrastructure for a much broader range of radiopharmaceutical therapies.
Our focus includes next-generation alpha therapies using Actinium-225, Lead-212 and Astatine-211, combined with targets such as PSMA, FAP, FAPI, HER2, GRPR and DLL3. These programs have the potential to extend radioligand therapy across prostate cancer and other solid tumors, making new radiopharmaceuticals and new cancer indications a core part of the ParticleX platform.
Lu-177 PSMA Moving to the Front of Care
First Clinical Use
First clinical experience with Lu-177 PSMA-617 showed that PSMA-targeted radiation could reach metastatic prostate cancer and produce meaningful tumor and PSA responses.
FDA Approval
Lu-177 PSMA received its first FDA approval for PSMA-positive mCRPC after AR pathway therapy and taxane chemotherapy.
Before Chemotherapy
The FDA expanded Lu-177 PSMA to PSMA-positive mCRPC after ARPI therapy for patients appropriate to delay taxane chemotherapy, moving treatment earlier in the disease course.
First line, alongside hormonal therapy
FDA approved Lu-177 PSMA with ARPI for PSMA-positive metastatic hormone-sensitive prostate cancer, bringing Lu-177 PSMA into use with hormonal therapy from the start of metastatic treatment.
Our Experience
15+ years building businesses in nuclear medicine and radiopharmmaceuticals.
PETSCAN Network
Engineering Division
Design and development of nuclear medicine center and radiopharmaceutical production facilities
International Experties
Designed and built facilities in Europe
Participated in the development of the Nuclear Research and Technology Center in Bolivia
What We’ll Need From Partners
Tell us about your practice
Tell us about your practice and we’ll explore how radioligand therapy can fit your patient flow.
Discuss patient volume
We'll review your patient population and identify which patients are candidates for radioligand therapy.
ParticleX moves
We engage with you to launch clinical development and operationalize the center.
Interested in Partnering with ParticleX ?
Tell us about your practice and we’ll get in touch.